Αρχική World News Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia

Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia

The use of infigratinib, the FGFR1–3 tyrosine kinase inhibitor in a 66 year old man with a phosphaturic mesenchymal tumour bearing the FN1FGFR1 fusion gene was reported in a letter to the editor on 9 September 2020 in The New England Journal of Medicine. Biochemical and structural response to the treatment with infigratinib confirms the role of FGFR1 signalling in phosphaturic mesenchymal tumour growth and FGF23 production.

Tumour-induced osteomalacia is a rare paraneoplastic syndrome caused by excessive secretion of FGF23 by a phosphaturic mesenchymal tumour. Through FGFR1 signalling, FGF23 decreases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production. Hypophosphatemia as a consequence causes rickets, osteomalacia, bone pain, muscle weakness and fractures.

Tumour-induced osteomalacia is usually cured by surgical resection of the phosphaturic mesenchymal tumour. When fusion genes consisting of FGFR1 and the gene encoding FN1 were identified in some phosphaturic mesenchymal tumours, FGFR1 emerged as a potential therapeutic target.

The authors described a case of the patient in whom phosphaturic mesenchymal tumour was diagnosed at the age of 42 years. The tumour persisted despite multiple surgeries. Lung metastases were diagnosed at age 56 and at age 61 the patient had widespread superficial and visceral metastases.

The treatment with infigratinib was started in the context of a clinical trial. The immediate response (within 24 hours) was recorded with decreased level of FGF23 which was after 2 weeks within normal values and the phosphate level elevated. Imaging revealed regression of metastases. With treatment, progressive calcification of several soft tissue lesions was observed. Pre- and post-treatment biopsies of one lesion revealed that a previously sarcomatous tumour had been replaced with lamellar bone, a finding consistent with metaplastic transformation.

Due to side effects, infigratinib has been discontinued after 18 months. The patient continued the treatment with nivolumab and ipilimumab in the context of a clinical trial, but this treatment was not effective. The FGF23 level continued to increase and metastases were widespread. Severe aneamia was treated with a transfusion. Granulocyte-colony stimulating factor–mediated paraneoplastic neutrophilia also developed.

Infigratinib was reinitiated 28 months after the previous discontinuation. The FGF23 level decreased again rapidly and imaging showed improvement. The side effects required intermittent dose interruptions. The disease progressed 10 months after resuming therapy and 5 years since the initiation of treatment with infigratinib, the patient died.

Infigratinib as a treatment for unresectable or non-localised phosphaturic mesenchymal tumours is currently evaluated in the NCT03510455 study.


Hartley IR, Miller CB, Papadakis GZ, et al. Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. NEJM; Published online 9 September 2020. DOI: 10.1056/NEJMc2020399.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...